Serious Skin Reactions
- Serious skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme) have been reported in patients receiving BEXTRA. Some of these reactions have resulted in death.
- Patients appear to be at higher risk for these events within the first 2 weeks of treatment, but these may occur at any time during treatment.
- The reported rate of these serious skin events appears to be greater for BEXTRA as compared to other COX-2 agents.
- BEXTRA should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
(See WARNINGS – Serious Skin Reactions)
|